

FertiTOX Main Assembly

05 & 11 June 2025

FertiTOX
Fertility after gonadotoxic treatments



- *Welcome*
- *General information*
- *Review of published studies*
- *Data presentation (update 04.06.2025, only eligible records)*
- *Follow-up (2nd visit)*
- *Laboratory parameters*
- *HORIZON grant*
- *Next meetings*
- *FertiPROTEKT Berlin, 24 – 25 April 2026*
- *Questions / Remarks*

Contributing Centres and their Ethics Application

Study registered at [ClinicalTral.gov](https://clinicaltrials.gov/ct2/show/study/NCT05885048) **NCT05885048**

Switzerland: 17 centres

- 17 centres of the Swiss network **FertiSAVE**

Austria: 5 centres

- **Innsbruck Uni**
- **Graz Uni**
- **Linz Uni**
- **Salzburg Uni**
- **Wien Uni**

Germany: 33 centres

- **Berlin** an der Gedächtniskirche
- **Berlin** Charité
- **Berlin** Fertility centre
- **Bonn** Uni
- **Bremen** Mitte Clinic
- **Dresden** Uni
- **Düsseldorf** UniKid
- **Erlangen** Uni
- **Freiburg** Uni
- **Gießen (Andro)** Uni
- **Hamburg** amedes expertes
- **Hannover** Uni
- **Heidelberg** Uni
- **Hildesheim** Fertility centre
- **Homburg (Saarland)** Uni
- **Karlsruhe** Klinikum
- **Kiel** Uni
- **Köln** MVZ PAN-Institute
- **Leipzig (Andro & Gyn)** Uni
- **Lübeck** Uni
- **Mainz** Uni
- **Mannheim** Uni
- **Marburg (Gyn)** Uni
- **München** LMU
- **München** TUM
- **Münster (Andro & Gyn)** Uni
- **Oldenburg** Fertility centre
- **Regensburg** Profertilita
- **Tübingen** Uni
- **Ulm** Uni
- **Wiesbaden** MVZ

Review of Published Studies

10 Systematic Reviews and Meta-Analyses (<https://fertitox.com>) Risk/prevalence of infertility (95% CI)


■ Bone cancer	Female 5 – 13% , Male 52 – 89%
■ Soft tissue sarcoma	Female 71% , Male 60%
■ Testicular cancer	14% (9 – 21%)
■ Cerebral cancer	20% (10 – 34%)
■ Bone marrow transplant	Female 65% (58 – 71%), Male 41% (32 – 51%)
■ Colorectal cancer	Female 27% (11 – 54%), Male 18% (13 – 26%)
■ Breast cancer	53% (41 – 64%) for AMH <0.5 ng/mL
■ Hodgkin's lymphoma	Female 21% (15 – 28%), Male 49% (36 – 62%)
■ Non-Hodgkin's lymphoma	Female 23% (14 – 35%), Male 35% (27 – 44%)
■ Leukaemia	<i>Middle of 2025, Charité, Berlin</i>

Overall Data by Disease

■ **Malignant diseases**

■ **Other diseases**

Total of 1100 eligible patients




Analysis of Overall Data by Sex from 20 German Centres

FertiTOX^D
Fertility after gonadotoxic treatments

Female: 425

Male: 322

Total of 747 eligible patients




Analysis of Overall Data by Sex from **17** Swiss Centres

FertiTOX
Fertility after gonadotoxic treatments

Female: 158

Male: 108

Total of 266 eligible patients




Analysis of Overall Data by Sex from 2 Austrian Centres

FertiTOX^A
Fertility after gonadotoxic treatments

■ Female: 58

■ Male: 29

Total of 87 eligible patients



Follow-up (2nd visit)

Organization of the 2nd Consultation

- **To centres:** Excel table with records with their estimated dates and any missing data
- **From centres:** medical letter from oncologist

Documentation of the 2nd Consultation → <https://fertitox.com/>

- Compact versions of the paper sheets (with ICD-10 list and WHOQOL-BREF)
- Translations (German, French, Italian, English)



Irene Marcu



irene.marcu@insel.ch



Kami Marie Schütz



Fertitox.FRAU@med.uni-heidelberg.de

Excel file

*You will also find **missing data** which should be completed when the patient comes back.*

	A	B	C	D	E	F	G	H	I	J	K	L	M
	REDCap Record ID	FertiTOX ICF	Diagnose	Diagnosedatum	Ende Gonadotoxizität	Nachuntersuchung 12 Monate ...	Nachuntersuchung ... 15 Monate	Fehlende Angaben	Offene Fragen	Uni ID	Sex	Geburtsjahr	Patientenkontaktdaten
1													
2			Hodgkin lymphoma (C81)		01.02.2024	31.01.2025	01.05.2025	° Stimulation cycles for oocyte freezing					
3			Hodgkin lymphoma (C81)		12.04.2024	12.04.2025	11.07.2025	° BMI (cm & kg)	3 semen samples, or straws?				
4			Hodgkin lymphoma (C81)		01.10.2024	01.10.2025	30.12.2025						
5			Colon carcinoma (C18)		30.11.2024	30.11.2025	28.02.2026						
6			Breast cancer - hormone receptor positive (Z17.0)		01.12.2024	01.12.2025	01.03.2026						
7			Stomach cancer (C16)		01.12.2024	01.12.2025	01.03.2026						
8			Breast cancer - hormone receptor negative (Z17.1)		01.12.2024	01.12.2025	01.03.2026	° Stimulation cycles for oocyte freezing					
9			Cervix uteri carcinoma (C53)		03.12.2024	03.12.2025	03.03.2026						
10			Leukemia lymphoid - acute lymphoblastic (C91.0)		26.12.2024	26.12.2025	26.03.2026	° Smoking ° Partnership ° Fertility					
11			Follikuläres Lymphom		26.12.2024	26.12.2025	26.03.2026	° Age of children					
12			Hodgkin lymphoma (C81)		30.12.2024	30.12.2025	30.03.2026						
13			Breast cancer - hormone receptor negative (Z17.1)		31.12.2024	31.12.2025	31.03.2026						
14			Colon carcinoma (C18)		31.12.2024	31.12.2025	31.03.2026						
15			Chorion-Ca		30.01.2025	30.01.2026	30.04.2026	° Partnership ° Fertility					
16			Hodgkin lymphoma (C81)		30.01.2025	30.01.2026	30.04.2026						
17			Breast cancer - hormone receptor positive (Z17.0)		30.01.2025	30.01.2026	30.04.2026	° Menstrual cycle parameters					
18			Testicular cancer - non seminomatous germ cell tumour - yolk sac carcinoma (C62)		30.01.2025	30.01.2026	30.04.2026	° Partnership ° Fertility ° Infertility					
19			Breast cancer - hormone receptor positive (Z17.0)	Missing	30.01.2025	30.01.2026	30.04.2026	° Diagnosedatum ° BMI (cm & kg)					
20			Breast cancer - hormone receptor negative (Z17.1)		30.01.2025	30.01.2026	30.04.2026	° Smoking ° Partnership ° Fertility ° Infertility ° Menstrual cycle parameters					
21			Hodgkin lymphoma (C81)		30.01.2025	30.01.2026	30.04.2026						
22			Hodgkin lymphoma (C81)		30.01.2025	30.01.2026	30.04.2026						
23			Breast cancer - hormone receptor positive (Z17.0)		31.01.2025	31.01.2026	01.05.2026						

Einladungsschreiben (Entwurf)

New Message

To | Cc Bcc

Subject

Sehr geehrte Frau...., Sehr geehrter Herr

Wir hoffen sehr, dass Sie ihre schwerwiegende Erkrankung gut überstanden haben und wieder in der Lage sind ihren Alltag zu meistern und zu genießen! Mittlerweile sollte seit dem Ende Ihrer Therapie (Chemotherapie, Antikörpertherapie, Bestrahlung, etc.) etwa ein Jahr vergangen sein. Es ist nun wichtig, Ihre Fertilität/Funktion der Eierstöcke/Hoden zu überprüfen, um Sie bei einer eingeschränkten Funktion weiter unterstützen zu können.

Bitte wenden Sie sich diesbezüglich bitte an unser Sekretariat und vereinbaren einen „Kontrolltermin Fertilitätsprotektion“ in unserer Praxis/Klinik. Dies ist sowohl für Ihre zukünftige Familienplanung als auch Ihre langfristige Gesundheit wichtig.

Bitte bringen Sie zu diesem Termin den Arztbrief des Onkologen, in dem die Art der Krebstherapie und deren Dauer erfasst ist, mit, damit wir Sie besser beraten können.

Sie erreichen uns unter:

Email:

Tel:

Mit freundlichem Gruß

↶ ↷ Sans Serif T B I U A ☰ ☷ ☹ ☺ ☻ ☼ ☽ ☾ ☿ ⚙ ✂


Send A 📎 🔗 😊 📷 🔒 ✎ ⋮

🗑

Laboratory Parameters

Primary endpoints that must be provided: **AMH concentration** and **SPERM concentration**.
The absence of other parameters is not a reason to exclude patients.

GONADOTOXICITY



Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer

[HORIZON-MISS-2024-CANCER-01-05](#)

“Prediction and prevention of late effects in AYA cancer survivors – An effort to understand, predict and prevent late effects in AYAs 15-39 years of age, with a focus on infertility and reproductive health PredictAYA”

- The coordinator is **Prof Rodriguez** from Sweden
- There are **18 partners**, including Heidelberg, Innsbruck and Bern
- **8 work packages**
- **Total: € 7 millions**

The work packages you could get involved with, starting January 2026:

- **WP4** (around 1.1 Mio): Clinical research on ovarian toxicity from large cohorts across Europe (coordinated by FertiTOX members)
- **WP6**: Late effect of cancer therapies on fertility and reproduction in males

Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer
[HORIZON-MISS-2024-CANCER-01-05](#)

“Prediction and prevention of late effects in AYA cancer survivors – An effort to understand, predict and prevent late effects in AYAs 15-39 years of age, with a focus on infertility and reproductive health PredictAYA”

- The contract has been **signed**.
- Patient recruitment is expected to begin on **January 1, 2026**.
- There will be **reimbursement** for patients enrolled in the study. However, the number of patients is limited per disease group.
- FertiTOX plans to retain the FertiTOX registry but expand it slightly via an **amendment** to allow the registry to include additional parameters for the PredictAYA project. The data would then be transferred to the PredictAYA registry.
- It will be clarified with the FertiTOX centers **whether** their data may be used for the PredictAYA project.

Next Meetings

(same content, different languages)

FertiTOX → Main Assembly



DEUTSCH

- 15.01.2026, *Donnerstag 18:00*
- 28.01.2026, *Mittwoch 15:00*

FertiTOX → Swiss registry



ENGLISH

- 15.01.2026, *Thursday 16:00*
- 28.01.2026, *Wednesday 18:00*

Contact



Switzerland

irene.marcu@insel.ch



michael.vonwolff@insel.ch



Germany

ariane.germeyer@med.uni-heidelberg.de



Fertitox.FRAU@med.uni-heidelberg.de



Austria

bettina.boettcher@i-med.ac.at

Sponsors

FertiTOX
Fertility after gonadotoxic treatments



krebsliga schweiz

Swiss cancer league



Deutsche Krebshilfe
HELLEN. FORSCHEN. INFORMIEREN.

Deutsche Krebshilfe



Caring Innovation

IBSA Institut Biochimique SA



Theramex
For Women, For Health

Theramex Switzerland GmbH

FERRING

PHARMACEUTICALS

Ferring Pharmaceuticals SA

Save the date – plus a free German book for participants

FertiTOX
Fertility after gonadotoxic treatments



20 Jahre
Ein Grund zum Feiern!

Wir laden euch herzlich ein zu einem besonderen Tag:

Tagsüber teilen wir Wissen – abends feiern wir mit euch!

Freut euch auf spannende Impulse, gute Gespräche und zum Abschluss einen unvergesslichen Abend mit musikalischen Highlights und guter Stimmung. **Anmeldung & weitere Infos über die Website.**


24. – 25.04.2026

Kaiserin-Friedrich-Haus, Berlin

<https://fertirotekt.com/aerzte-fachpersonen/kongresse-veranstaltungen/>



Completely revised and extended new editions in 2026



Questions / Remarks